Peroxidase-mediated Bioactivation of Hydroxylated Metabolites of Carbamazepine and Phenytoin
Overview
Authors
Affiliations
Carbamazepine (CBZ) and phenytoin (PHN) are associated with a relatively high incidence of idiosyncratic drug reactions. Most such reactions are believed to be due to reactive metabolites. The reactions associated with these two drugs are similar, and if a patient has a reaction to one, he or she is at increased risk of having a reaction to the other, suggesting that a similar reactive metabolite may be involved. CBZ causes neutropenia in approximately 10% of patients; this suggests that reactive metabolites are formed by myeloperoxidase (MPO), the major oxidative enzyme in neutrophils. Major metabolites of CBZ are the 2- and 3-OH metabolites, and that of PHN is the 4-OH metabolite. We found that both 2-OH-CBZ and 3-OH-CBZ were further oxidized by MPO/H2O2, and the oxidation of 3-OH-CBZ was much faster than the oxidation of 2-OH-CBZ or CBZ itself. Oxidation by MPO formed dimers of 3-OH-CBZ and 4-OH-PHN and, in the presence of N-acetyltyrosine, cross dimers were formed. This strongly suggests free radical intermediates. Bioactivation of 3-OH-CBZ and 4-OH-PHN by MPO/H2O2 led to covalent binding to the tyrosine of a model protein. Free radicals usually generate reactive oxygen species (ROS). We also tested the ability of these metabolites to generate ROS and found that 3-OH-CBZ generated more ROS than 2-OH-CBZ, which was, in turn, greater than that generated by CBZ. These results suggest that bioactivation of 3-OH-CBZ and 4-OH-PHN to free radicals by peroxidases may play a role in the ability of these drugs to cause idiosyncratic drug reactions.
Martinc B, Grabnar I, Milosheska D, Lorber B, Vovk T Medicina (Kaunas). 2024; 60(8).
PMID: 39202580 PMC: 11356379. DOI: 10.3390/medicina60081299.
Evaluation of clinical and genetic factors in the population pharmacokinetics of carbamazepine.
Yip V, Pertinez H, Meng X, Maggs J, Carr D, Park B Br J Clin Pharmacol. 2020; 87(6):2572-2588.
PMID: 33217013 PMC: 8247401. DOI: 10.1111/bcp.14667.
Zhou Y, Oh M, Kim Y, Kim E, Kang J, Chung S Molecules. 2020; 25(8).
PMID: 32294954 PMC: 7221793. DOI: 10.3390/molecules25081775.
Pylypchuk I, Daniel G, Kessler V, Seisenbaeva G Nanomaterials (Basel). 2020; 10(2).
PMID: 32046049 PMC: 7075194. DOI: 10.3390/nano10020282.
Hepatic Bioactivation of Skin-Sensitizing Drugs to Immunogenic Reactive Metabolites.
Chong L, Ng C, Li H, Tian E, Ananthanarayanan A, McMillian M ACS Omega. 2019; 4(9):13902-13912.
PMID: 31497708 PMC: 6714514. DOI: 10.1021/acsomega.9b01551.